Netherlands· NL-bbf01c47dc68
Oxlumo 189 mg/ml, oplossing voor injectie
A lumasiran product containing lumasirannatrium, registered in Netherlands by Alnylam Netherlands B.V.. The same ATC class is registered in 12 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Lumasiran is registered in 12 of 19 countries.
Countries holding a registration under ATC A16AX18 (lumasiran), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 8 of them publish a price we can compare per daily dose
Lumasiran · ATC A16AX18
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- LUMASIRANNATRIUM
- Manufacturer
- Alnylam Netherlands B.V.
- Country
- Netherlands (NL)
- ATC code
- A16AX18
- ATC class
- Lumasiran
- Defined daily dose
- 2.3 mg, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/20/1496
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lumasiran in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FranceOXLUMO 94,5 mg/0,5mL, solution injectableALNYLAM NETHERLANDS (PAYS-BAS)
- CanadaOXLUMOALNYLAM NETHERLANDS B.V.
- SwitzerlandOxlumo 94.5 mg / 0.5 ml, InjektionslösungAlnylam Switzerland GmbH
- SpainOXLUMO 94,5 mg/0,5 ml SOLUCION INYECTABLEAlnylam Netherlands B.V.
- United KingdomOxlumo 94.5mg/0.5ml solution for injection vialsAlnylam UK Ltd
- IcelandOxlumoAlnylam Netherlands B.V.
- PolandOxlumoAlnylam Netherlands B.V.
- SwedenOxlumo 94,5 mg/0,5 ml Injektionsvätska, lösningAlnylam Netherlands B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Oxlumo
- Liechtenstein · Oxlumo
- Norway · Oxlumo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/481f77fe-22cf-439b-a855-57a4a563d7a1 GET /v1/drugs/481f77fe-22cf-439b-a855-57a4a563d7a1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oplossing voor injectie",
"route": "Subcutaan gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/oxlumo-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Lumasiran",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp126668",
"excipients": [
"FOSFORZUUR (E 338)",
"NATRIUMHYDROXIDE (E 524)",
"WATER VOOR INJECTIE"
],
"substances": [
"LUMASIRANNATRIUM"
],
"leaflet_url": null,
"authorised_at": "2020/11/19",
"procedure_number": "EMEA/H/C/005040",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/20/1496",
"additional_monitoring": "N"
}See everything about lumasiran.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.